cat crl 1593 2tm Search Results


u937  (ATCC)
99
ATCC u937
Determining optimal RESV dosage inducing apoptosis of <t>U937</t> and primary human MDMs. Representative graphs for time-course cell death of PMA-differentiated U937 cells (A) and primary human MDMs (B) induced by AEG40730 and RESV.
U937, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/u937/product/ATCC
Average 99 stars, based on 1 article reviews
u937 - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
cat crl 1593 2tm  (ATCC)
99
ATCC cat crl 1593 2tm
Determining optimal RESV dosage inducing apoptosis of <t>U937</t> and primary human MDMs. Representative graphs for time-course cell death of PMA-differentiated U937 cells (A) and primary human MDMs (B) induced by AEG40730 and RESV.
Cat Crl 1593 2tm, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cat crl 1593 2tm/product/ATCC
Average 99 stars, based on 1 article reviews
cat crl 1593 2tm - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


Determining optimal RESV dosage inducing apoptosis of U937 and primary human MDMs. Representative graphs for time-course cell death of PMA-differentiated U937 cells (A) and primary human MDMs (B) induced by AEG40730 and RESV.

Journal: RNA Biology

Article Title: Transfection of hard-to-transfect primary human macrophages with Bax siRNA to reverse Resveratrol-induced apoptosis

doi: 10.1080/15476286.2020.1730081

Figure Lengend Snippet: Determining optimal RESV dosage inducing apoptosis of U937 and primary human MDMs. Representative graphs for time-course cell death of PMA-differentiated U937 cells (A) and primary human MDMs (B) induced by AEG40730 and RESV.

Article Snippet: U937 (ATCC Cat. CRL-1593.2TM) was maintained in complete medium (DMEM from Wisent, Cat.: 319-105-CL; 10% Foetal Bovine Serum (FBS) from Sigma, SKU: F1051; 100U/ml Penicillin G from Sigma, SKU: P3032; 100μg/ml Streptomycin from Sigma, SKU: S9137) at 37°C, 5% CO 2 at the density of 10 5 ~ 10 6 cells/ml.

Techniques:

Transfection reagent selection for U937 and human macrophages. 20 nM Bax siRNA was transfected with 3 different doses of each transfection reagent (the amount recommended by the manufacturer, +25% and −25% of the dose recommended by the manufacturer). For clarity and ease of presentation, the best two kill curves for the transfection reagents closest to the ‘no treatment curve’ are shown. If the best two curves selected for a transfection reagent were very close to each other, however, only one curve is shown. Representative graph for the time-course cell death of PMA-differentiated U937 cells (A) and primary human MDMs (B) pretreated with Bax siRNA 24 hr before treatment with RESV. (C) The cytotoxicity comparison between DharmaFECT 3 and Lipofectamine 2000 in primary human MDMs. 20 nM BLOCK-iT™ Alexa Fluor® Red Fluorescent control siRNA was transfected with either 1.0 μl DharmaFECT 3 or 6.0 μl Lipofectamine 2000 for 16 hr following which the cells were imaged under fluorescence microscope.

Journal: RNA Biology

Article Title: Transfection of hard-to-transfect primary human macrophages with Bax siRNA to reverse Resveratrol-induced apoptosis

doi: 10.1080/15476286.2020.1730081

Figure Lengend Snippet: Transfection reagent selection for U937 and human macrophages. 20 nM Bax siRNA was transfected with 3 different doses of each transfection reagent (the amount recommended by the manufacturer, +25% and −25% of the dose recommended by the manufacturer). For clarity and ease of presentation, the best two kill curves for the transfection reagents closest to the ‘no treatment curve’ are shown. If the best two curves selected for a transfection reagent were very close to each other, however, only one curve is shown. Representative graph for the time-course cell death of PMA-differentiated U937 cells (A) and primary human MDMs (B) pretreated with Bax siRNA 24 hr before treatment with RESV. (C) The cytotoxicity comparison between DharmaFECT 3 and Lipofectamine 2000 in primary human MDMs. 20 nM BLOCK-iT™ Alexa Fluor® Red Fluorescent control siRNA was transfected with either 1.0 μl DharmaFECT 3 or 6.0 μl Lipofectamine 2000 for 16 hr following which the cells were imaged under fluorescence microscope.

Article Snippet: U937 (ATCC Cat. CRL-1593.2TM) was maintained in complete medium (DMEM from Wisent, Cat.: 319-105-CL; 10% Foetal Bovine Serum (FBS) from Sigma, SKU: F1051; 100U/ml Penicillin G from Sigma, SKU: P3032; 100μg/ml Streptomycin from Sigma, SKU: S9137) at 37°C, 5% CO 2 at the density of 10 5 ~ 10 6 cells/ml.

Techniques: Transfection, Selection, Comparison, Blocking Assay, Control, Fluorescence, Microscopy

Protective effects of Bax siRNA in PMA-differentiated U937 cells. A1: RESV treated for 24 hr; A2: RESV treated for 48 hr; B1: No RESV treatment 24 hr; B2: No RESV treatment 48 hr; C1: Pretreated with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 24 hr then RESV treated for 24 hr; C2: Pretreated with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 24 hr then RESV treated for 48 hr. D: Number of dead cells in A1, B1, C1 and A2, B2, C2, information directly retrieved from Incucyte®. E: Percentage of dead cells compared to RESV treated; F: Representative Western blot analysis of PMA-differentiated U937 cells transfected with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 48 hr. G: Densitometry analysis of BAX and β-Actin protein bands from three independent Western blot experiments with results shown as mean ± SD (n = 3). * indicates p ≤ 0.05. ** indicates p ≤ 0.01.

Journal: RNA Biology

Article Title: Transfection of hard-to-transfect primary human macrophages with Bax siRNA to reverse Resveratrol-induced apoptosis

doi: 10.1080/15476286.2020.1730081

Figure Lengend Snippet: Protective effects of Bax siRNA in PMA-differentiated U937 cells. A1: RESV treated for 24 hr; A2: RESV treated for 48 hr; B1: No RESV treatment 24 hr; B2: No RESV treatment 48 hr; C1: Pretreated with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 24 hr then RESV treated for 24 hr; C2: Pretreated with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 24 hr then RESV treated for 48 hr. D: Number of dead cells in A1, B1, C1 and A2, B2, C2, information directly retrieved from Incucyte®. E: Percentage of dead cells compared to RESV treated; F: Representative Western blot analysis of PMA-differentiated U937 cells transfected with 20 nM Bax siRNA and 1.0 µl DharmaFECT 3 for 48 hr. G: Densitometry analysis of BAX and β-Actin protein bands from three independent Western blot experiments with results shown as mean ± SD (n = 3). * indicates p ≤ 0.05. ** indicates p ≤ 0.01.

Article Snippet: U937 (ATCC Cat. CRL-1593.2TM) was maintained in complete medium (DMEM from Wisent, Cat.: 319-105-CL; 10% Foetal Bovine Serum (FBS) from Sigma, SKU: F1051; 100U/ml Penicillin G from Sigma, SKU: P3032; 100μg/ml Streptomycin from Sigma, SKU: S9137) at 37°C, 5% CO 2 at the density of 10 5 ~ 10 6 cells/ml.

Techniques: Western Blot, Transfection